Company Overview
Apellis Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel therapeutic compounds designed to address diseases characterized by significant unmet medical needs. The company functions within the Healthcare sector and specifically within the Biotechnology industry, a classification that defines its focus on innovative drug development rather than established manufacturing or generic pharmaceuticals. The firm maintains a market capitalization of $2.20B and reports annual revenue of $1.00B, supported by an organizational workforce of 733 employees. These financial dimensions indicate that the company holds a substantial market position within the biotechnology landscape, possessing sufficient scale to fund ongoing research and commercialization efforts while maintaining a significant enterprise value relative to its peer group.
Financial Health
The company reported revenue of $1.00B over the trailing twelve months, with net income of $22.39M and EBITDA of $56.98M, illustrating a distinct gap between top-line generation and bottom-line profitability that reveals a cost structure heavily influenced by high operating expenses or non-operating costs. This structural dynamic is further highlighted by a free cash flow figure of -$15,464,500, which indicates a period of net cash outflow that necessitates a reliance on existing cash reserves to fund operations and strategic initiatives. The profitability profile is segmented by three key margins: a gross margin of 60.3%, which reflects efficient production relative to sales; an operating margin of -25.6%, suggesting that operating expenses currently exceed operating income; and a profit margin of 2.2%, demonstrating that the company generates a minimal net profit relative to total revenue. Liquidity and solvency are assessed through a cash balance of $467.79M contrasted against total debt of $474.36M, resulting in a debt-to-equity ratio of 128.15, which characterizes the balance sheet as highly leveraged given that debt slightly exceeds cash holdings. Short-term liquidity is robust, evidenced by a current ratio of 3.14, which implies the company holds more than three times the current assets necessary to meet its short-term obligations. Return metrics show a return on equity of 7.5% and a return on assets of 3.5%, figures that reveal management's effectiveness in generating returns relative to shareholder equity and total asset base, respectively.
Valuation Assessment
Valuation multiples for the stock include a trailing P/E ratio of 95.61 and a forward P/E of -60.68, where the negative forward P/E implies that the market expects earnings to remain negative in the near term, preventing a traditional forward multiple calculation and signaling anticipated losses. The price-to-book ratio stands at 5.89, indicating that the market values the company at nearly six times its book value, which suggests a significant premium assigned to the company's intangible assets and future growth potential compared to its net asset value. Alternative valuation perspectives include a price-to-sales ratio of 2.19 and an EV/EBITDA of 38.72, metrics that suggest investors are pricing the company based on sales volume and enterprise earnings power rather than current profitability, a common practice for biotechnology firms in development stages. Price volatility and trading ranges are defined by a 52-week high of $30.48 and a 52-week low of $16.10, establishing a wide trading band within which the current price fluctuates. The stock exhibits a beta of 0.29, a figure that signifies the company's price movements are less volatile than the broader market, suggesting a defensive characteristic often found in specialized biotechnology portfolios.
Growth & Income
Revenue growth year-over-year is recorded at -5.9%, while earnings growth is marked as N/A due to the lack of comparable prior period earnings data required for calculation. The absence of a positive earnings growth rate relative to revenue implies that the company is in a phase where revenue contraction or stagnation is not being offset by proportional earnings improvements, reflecting the challenges of scaling a biopharmaceutical portfolio. Regarding income distribution, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm does not distribute dividends to shareholders. Consequently, the company retains all earnings and reinvests capital directly into research and development, clinical trials, and commercial expansion rather than paying out income. The overall growth and income profile is defined by a lack of current dividend income and negative revenue growth, positioning the stock purely as a capital appreciation vehicle dependent on future drug approvals and market uptake rather than current yield or expansion metrics.